7.060

-0.060 (-0.84%)
Range 6.940 - 7.210   (3.89%)
Open 7.050
Previous Close 7.120
Buy Price 6.730
Buy Volume 22
Sell Price 7.400
Sell Volume 8
Volume 621,314
Value -
Remark
Measurement Type Value
EPS (USD) 1.456
Trailing EPS (USD) 1.456
NAV (USD) 8.532
Cash In Hand (USD) 9.184
Dividend -
Dividend Yield (%) -
PE 4.745
Trailing PE 4.745
Price / NAV 0.81
Price / Cash In Hand 0.752
Issued & Paid-up Shares 83,225,600
Treasury Shares -
Market Cap (M) 575.089
Par Value (USD) n.a.
Beta - 75 Days 1.422
R-Squared - 75 Days(%) 43.58
Beta - 500 Days -11.272
R-Squared - 500 Days(%) 0.74
ISIN Code
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 29 Jun 2022 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 09 Aug 2022
View All Events

About ATEA PHARMACEUTICALS INC

Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals Inc., is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options. Its product candidates include vapendavir, which is an oral treatment for human rhinovirus (HRV) infections in moderate-to-severe asthmatics that is being evaluated in its Phase IIb SPIRITUS trial; BTA074, a Phase II topical antiviral treatment for genital warts caused by human papillomavirus (HPV) types 6 and 11; BTA585, an oral fusion (F) protein inhibitor in Phase IIa development for the treatment and prevention of respiratory syncytial virus (RSV)-A and RSV-B infections, and laninamivir octanoate in Phase II development for the treatment of influenza A and B infections. It also has preclinical RSV non-fusion inhibitor program.

There are 1 follower

Followers
2